Cantor Fitzgerald Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Cantor Fitzgerald initiated coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI - Free Report) in a report issued on Tuesday, MarketBeat reports. The firm issued an overweight rating and a $10.00 price objective on the stock.

A number of other analysts have also issued reports on TLSI. Northland Securities started coverage on TriSalus Life Sciences in a report on Friday, October 25th. They issued an "outperform" rating and a $12.50 target price on the stock. Roth Mkm started coverage on TriSalus Life Sciences in a research report on Monday, November 11th. They set a "buy" rating and a $11.00 target price for the company. Oppenheimer started coverage on TriSalus Life Sciences in a research report on Monday, September 16th. They set an "outperform" rating and a $10.00 target price for the company. Northland Capmk upgraded TriSalus Life Sciences to a "strong-buy" rating in a research report on Friday, October 25th. Finally, Roth Capital upgraded TriSalus Life Sciences to a "strong-buy" rating in a research report on Monday, November 11th. Seven analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $11.79.

TriSalus Life Sciences Stock Down 1.8 %

Shares of TLSI traded down $0.07 during midday trading on Tuesday, reaching $3.81. 16,135 shares of the stock were exchanged, compared to its average volume of 39,594. The company has a market cap of $116.18 million, a price-to-earnings ratio of -1.53 and a beta of 0.56. The firm has a 50 day simple moving average of $4.17 and a 200-day simple moving average of $4.98. TriSalus Life Sciences has a 12-month low of $3.50 and a 12-month high of $10.42.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently added to or reduced their stakes in TLSI. Virtu Financial LLC bought a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $92,000. Geode Capital Management LLC lifted its stake in shares of TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock valued at $924,000 after acquiring an additional 62,542 shares during the last quarter. Vestcor Inc bought a new position in shares of TriSalus Life Sciences in the 3rd quarter valued at $108,000. MSD Partners L.P. bought a new position in TriSalus Life Sciences during the 3rd quarter worth $184,000. Finally, Walleye Capital LLC acquired a new stake in TriSalus Life Sciences during the 3rd quarter worth about $66,000. Institutional investors and hedge funds own 2.58% of the company's stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.